key points from the revel trial in nsclc
Published 6 years ago • 26 plays • Length 3:09Download video MP4
Download video MP3
Similar videos
-
2:26
the phase 3 revel trial in nsclc
-
2:26
the revel study in lung cancer
-
5:13
the revel trial and subanalysis
-
4:14
clinical implications of the revel trial in nsclc
-
6:18
treating nsclc with ramucirumab: the revel trial
-
2:37
exploratory analysis of frontline therapies in revel: phase 3 trial of ramucirumab in nsclc
-
6:53
nsclc: rapid progression data in the revel trial
-
2:35
exploratory analysis of frontline therapies in revel: a phase 3 trial of ramucirumab in nsclc
-
2:48
ramucirumab in relapsed/refractory nsclc
-
2:34
key trials that will affect the therapy landscape for nsclc
-
5:13
clinical trial for early-stage non-small cell lung cancer following surgery
-
5:18
second-line treatment with ramucirumab plus docetaxel extends survival in advanced nsclc
-
1:50
anti-vegf therapy in advanced squamous nsclc
-
3:45
ramucirumab plus docetaxel extends survival in advanced nsclc
-
1:00:44
practical application of recent clinical data for immunotherapy in nsclc
-
3:16
phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer
-
45:17
iclio webinar: reflex testing guidelines for immunotherapy in non small cell lung cancer
-
8:11
first-line immunotherapy: impower133 regimen
-
4:51
lung cancer trial for patients with prior response to immunotherapy